Abbott Story

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;'>AL</div>
ABT -- USA Stock  

USD 107.62  1.21  1.14%

Abbott Laboratories is scheduled to announce its earnings today. The next earnings report is expected on the 27th of January 2021. As many retail investors are getting excited about healthcare space, it is fair to review Abbott Laboratories outlook under the newest economic conditions. What exactly are Abbott Laboratories shareholders getting in November?
Published over a month ago
View all stories for Abbott Laboratories | View All Stories
Should you continue to hold Abbott Laboratories (NYSE:ABT) based on the newest analyst consensus?
Abbott Laboratories is UNDERVALUED at 120.89 per share with modest projections ahead. Macroaxis provides advice on Abbott Laboratories to complement and cross-verify current analyst consensus on Abbott Laboratories. Our investment recommendation engine determines the company's potential to grow exclusively from the perspective of an investor's current risk tolerance and investing horizon.
What is the right price you would pay to acquire a share of Abbott Laboratories? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

What is happening with Abbott Laboratories this year

Annual and quarterly reports issued by Abbott Laboratories are formal financial statements that are published yearly and quarterly and sent to Abbott stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934. Companies such as Abbott Laboratories often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How Abbott utilizes its cash?

To perform a cash flow analysis of Abbott Laboratories, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Abbott Laboratories is receiving and how much cash it distributes out in a given period. The Abbott Laboratories cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Abbott Laboratories Net Cash Flow from Operations is comparatively stable at the moment as compared to the past year. Abbott Laboratories reported Net Cash Flow from Operations of 6.14 Billion in 2019

Detailed Perspective On Abbott Laboratories

Earning per share calculations of Abbott Laboratories is based on official Zacks consensus of 7 analysts regarding Abbott Laboratories' future annual earnings. Given the historical accuracy of 99.05%, the future earnings per share of the company is estimated to be 3.302 with the lowest and highest values of 3.25 and 3.51, respectively. Please note that this consensus of annual earnings estimates for the firm is an estimate of EPS before non-recurring items and including employee stock options expenses.

Is Abbott a risky opportunity?

Let's check the volatility. Abbott is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Abbott (NYSE:ABT) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. acquiring a share of an Abbott Laboratories stock makes you a part-owner of that company.

Abbott Laboratories Current Consensus

Here is the newest trade recommendation based on an ongoing consensus estimate among financial analysis covering Abbott Laboratories. The Abbott consensus assessment is calculated by taking the average estimates from all of the analysts covering Abbott Laboratories

Strong Buy
11
Buy
1
Hold
3
Strong Buy1173.33
Buy16.67
Hold320.0
Sell00.0
Strong Sell00.0

Abbott may start a recoup in November

The semi deviation is down to 1.3 as of today. Abbott Laboratories has relatively low volatility with skewness of 1.13 and kurtosis of 3.86. However, we advise all investors to independently investigate Abbott Laboratories to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.

Our Final Perspective on Abbott Laboratories

Whereas other companies under the medical devices industry are still a bit expensive, Abbott Laboratories may offer a potential longer-term growth to private investors. Taking everything into account, as of the 21st of October 2020, we believe that at this point, Abbott Laboratories is very steady with low odds of financial turmoil within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. Our latest 30 days buy vs. sell advice on the firm is Strong Buy.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Abbott Laboratories. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com